newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) th